AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38060199
Drug: Triplet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet therapy
Trial: 38060545
Drug: Psychoeducational video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational video prescriptions about BPD
Trial: 38060545
Drug: Psychoeducational video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational video prescriptions about non-BPD mental health topics
Trial: 38060549
Drug: Placebo medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medicine
Trial: 38060997
Drug: Transcatheter edge-to-edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge-to-edge repair (TEER) with the MitraClip™ device plus guideline-directed medical therapy (GDMT)
Trial: 38061271
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group)
Trial: 38061367
Drug: VAX-24 (1·1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens)
Trial: 38061367
Drug: VAX-24 (2·2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX-24 (2·2 μg)
Trial: 38061370
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg once per day
Trial: 38061376
Drug: Three-drug nevirapine-based
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-drug nevirapine-based ART (cohort 1)
Trial: 38061376
Drug: Three-drug nevirapine-based
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-drug nevirapine-based prophylaxis followed by three-drug nevirapine-based ART (cohort 2)
Trial: 38061553
Drug: EMDR therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMDR therapy and ST
Trial: 38062157
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for obesity for 8 weeks
Trial: 38062475
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 10 weeks focusing on anxiety
Trial: 38064219
Drug: Trauma Center
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Center Trauma-Sensitive Yoga (TCTSY) - 10 weekly, 60-minute group sessions
Trial: 38064219
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) - 12 weekly, 90-minute group sessions
Trial: 38064260
Drug: S(+)-ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)-ketamine (0.3 mg/kg/h)
Trial: 38064262
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily steps (measured using Fitbit-HR Charge 2)
Trial: 38064262
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily steps
Trial: 38064262
Drug: Step trajectories
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step trajectories during treatment
Trial: 38064454
Drug: Extracorporeal cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal cardiac shock wave therapy (ECSW) combined with optimal drug therapy
Trial: 38065203
Drug: Sabatolimab plus
RxNorm normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabatolimab plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Trial: 38065203
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Trial: 38065203
Drug: Sabatolimab plus
RxNorm normalized name: Sabatolimab
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabatolimab plus hypomethylating agent
Trial: 38065203
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus hypomethylating agent
Trial: 38065326
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy after 6 months in patients with PDL at the lobe
Trial: 38065906
Drug: CKD-495 75
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-495 75 mg
Trial: 38065906
Drug: AAF 60
RxNorm normalized name: Filgrastim-aafi
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAF 60 mg
Trial: 38066442
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 10 cc sterile processed acellular hAF once daily for up to 5 days
Trial: 38066471
Drug: Rectal microbicide
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal microbicide modalities (douche, insert, suppository)
Trial: 38066522
Drug: anti-PD-1 immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 immunotherapy
Trial: 38066597
Drug: Exenatide (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (once weekly) plus standard treatment
Trial: 38368603
Drug: Somapacitan (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan (0.16 mg/kg/week)
Trial: 38368603
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH (0.034 mg/kg/day)
Trial: 38067150
Drug: IL-6 protein
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 protein levels of ≥6.4 pg/mL
Trial: 38068830
Drug: Automated Self-Administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated Self-Administered 24-h Dietary Assessment Tool (ASA24) for food records.
Trial: 38070031
Drug: IFNβ-1a plus
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFNβ-1a plus 2 gm of metformin once daily
Trial: 38070635
Drug: PCSK9 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors (alirocumab 150 mg sc or evolocumab 140 mg sc every two weeks)
Trial: 38070683
Drug: Cocoa extract
RxNorm normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa extract (CE) 500 mg flavanols/d, including 80 mg (-)-epicatechin
Trial: 38070682
Drug: Folic acid-containing
RxNorm normalized name: Folic acid-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid-containing supplements during treatment
Trial: 38070682
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid in plasma during treatment
Trial: 38070892
Drug: Antibody levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody levels
Trial: 38071986
Drug: Reduction group
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction group (ICS-formoterol dose tapering)
Trial: 38071990
Drug: SIM01 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIM01 (10 billion colony-forming units in sachets twice daily)
Trial: 38072158
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg intravenously every 3 weeks for ≤93 weeks
Trial: 38072183
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 (2800 IU/d)
Trial: 38072183
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose vitamin D3 (400 IU/d)
Trial: 38072494
Drug: Low birth
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birth weight (<2500 g)
Trial: 38072513
Drug: Lasofoxifene 5
RxNorm normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Lasofoxifene 5 mg/day plus abemaciclib 150 mg b.i.d until disease progression/toxicity
Trial: 38072514
Drug: Lasofoxifene 5
RxNorm normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Lasofoxifene 5 mg daily
Trial: 38072514
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (days 1, 15, and 29, then every 4 weeks)
Trial: 38072625
Drug: Lisocabtagene maraleucel
RxNorm normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10
Trial: 38072743
Drug: Pomalidomide, Bortezomib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide, Bortezomib, and Dexamethasone (PVd) with bortezomib dose adjustment
Trial: 38073038
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg daily for 14 days
Trial: 38073563
Drug: Hypertensive individuals
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertensive individuals (systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or use of antihypertensive medications) at 1 year postpartum
Trial: 38074312
Drug: Sotrovimab treatment
RxNorm normalized name: sotrovimab
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Sotrovimab treatment
Trial: 38074489
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for obesity management, combined with sessions with a dietitian and a kinesiologist, for 16 weeks.
Trial: 38074489
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving sessions with a dietitian and a kinesiologist, without cognitive behavioral therapy, for 16 weeks.
Trial: 38074489
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for obesity management.
Trial: 38074719
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg THC mixed with tobacco
Trial: 38074719
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg THC mixed with tobacco
Trial: 38075956
Drug: Home-based Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based Exercise Therapy (HBET) program with behavior change intervention and smartphone app
Trial: 38076348
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (eGFR <30 ml/min/1.73 m²)
Trial: 38076348
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (eGFR ≥30 and <60 ml/min/1.73 m²)
Trial: 38076348
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (eGFR ≥60 ml/min/1.73 m²)
Trial: 38076682
Drug: ADHD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD group (medicated daily for ADHD)
Trial: 38077624
Drug: MF59 adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59 adjuvanted trivalent influenza vaccine (aTIV)
Trial: 38078711
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of tributaries
Trial: 38078711
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of perforating veins
Trial: 38078870
Drug: Tirzepatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (10 or 15 mg, once-weekly subcutaneous)
Trial: 38078898
Drug: Camonsertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camonsertib monotherapy
Trial: 38079084
Drug: PG-HPG nanoemulsion
RxNorm normalized name: linoleamidopropyl PG-dimonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG-HPG nanoemulsion lubricant eye drops, self-administered one drop four times daily for 28 ± 2 days
Trial: 38079089
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg once daily orally until disease progression or unacceptable toxicity
Trial: 38079095
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg oral daily
Trial: 38079095
Drug: Probe drug
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe drug alone
Trial: 38081585
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (15% energy, 30-60 g/d; 2.6-5.2 g C18:3n-3/d)
Trial: 38082227
Drug: 1 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg/kg dexmedetomidine
Trial: 38082231
Drug: FPSS (flavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPSS (flavored PEG and sulfate solution)
Trial: 38082248
Drug: Weekly reminders
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly reminders (WR) group - received phone reminders 1x/week for 10 weeks
Trial: 38082351
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (MCI) program including education of ICU professionals, identification of patients at risk for agitation, formulation of a multidisciplinary person-centered care plan, and protocolized goal-directed light sedation using dexmedetomidine.
Trial: 38084725
Drug: 90 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g of donor faeces once into the large intestine
Trial: 38084725
Drug: 90 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g of donor faeces once into the small intestine
Trial: 38084725
Drug: 90 g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g of donor faeces twice into the small intestine
Trial: 38084760
Drug: Daratumumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab combined with VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group)
Trial: 38084760
Drug: VRd induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group)
Trial: 38084906
Drug: Daily samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily samples for 10 days
Trial: 38084906
Drug: Daily rapid
RxNorm normalized name: Clotam Rapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rapid antigen tests (RATs)
Trial: 38085312
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg orally twice per day from enrollment through delivery
Trial: 38085312
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice per day from enrollment through delivery
Trial: 38085470
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) administration of CoronaVac
Trial: 38085470
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) administration of CoronaVac
Trial: 38085846
Drug: Riliprubart 30
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riliprubart 30 mg/kg
Trial: 38085846
Drug: Riliprubart 15
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riliprubart 15 mg/kg
Trial: 38085846
Drug: Riliprubart (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riliprubart (both doses)
Trial: 38086444
Drug: Buprenorphine (offered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (offered to participants taking prescription opioid medications at an average dose of ≥20 morphine milligram equivalents per day)
Trial: 38086587
Drug: Medical hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical hypnosis (MH) and cardiac coherence (CC) training, starting 7 days before surgery.
Trial: 38086587
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment to manage preoperative anxiety (Control).
Trial: 38086587
Drug: Medical hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical hypnosis (MH) and cardiac coherence (CC) training.
Trial: 38086595
Drug: Methylphenidate (long-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (long-release capsule, doses 18-36-54 mg)
Trial: 38086595
Drug: Lisdexamphetamine (LDX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamphetamine (LDX, 30-50-70 mg)
Trial: 38086998
Drug: Imaradenant 50
RxNorm normalized name: Imaradenant
DrugBank: Imaradenant (DB16192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaradenant 50 mg QD
Trial: 38086998
Drug: Imaradenant 75
RxNorm normalized name: Imaradenant
DrugBank: Imaradenant (DB16192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaradenant 75 mg QD
Trial: 38086998
Drug: Imaradenant (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaradenant (50 mg and 75 mg QD)
Trial: 38088154
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity measured by wearable smartwatch (Huawei smartwatch)
Trial: 38088154
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step counts
Trial: 38088156
Drug: Standard immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppression treatment with eltrombopag (Group B)
Trial: 38088156
Drug: Standard immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppression treatment (Group A)
Trial: 38089057
Drug: Peroral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroral administration of a capsule containing purified DMT and harmine
Trial: 38089057
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of an oromucosal harmine tablet and an intranasal DMT spray
Trial: 38089061
Drug: Combined supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplement of standardized dry extracts of amla
Trial: 38089924
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g broccoli sprouts
Trial: 38090266
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta-1a (sc IFN β-1a) treatment
Trial: 38090987
Drug: Eplerenone, 50
RxNorm normalized name: Eplerenone, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone, 50 mg, twice a day
Trial: 38091531
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant influenza vaccine (Flublok Quadrivalent)
Trial: 38091531
Drug: Standard-dose influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose influenza vaccines
Trial: 38091530
Drug: mRNA-1345 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1345 (50 μg)
Trial: 38092009
Drug: Golidocitinib 150
RxNorm normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met.
Trial: 38092009
Drug: Golidocitinib 150
RxNorm normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib 150 mg once daily
Trial: 38092151
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid (FA) supplementation at 800 μg/day for 12 weeks
Trial: 38092153
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg oral daily)
Trial: 38092225
Drug: Dupilumab 100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 100/200 mg by bodyweight every 2 weeks for 52 weeks
Trial: 38092272
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice nitrate-rich (BRJ-NO3), 800 mg of NO